Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 30, Number 3—March 2024
CME ACTIVITY - Research

Disseminated Leishmaniasis, a Severe Form of Leishmania braziliensis Infection

Paulo R.L. MachadoComments to Author , Alexsandro Lago, Thiago M. Cardoso, Andréa Magalhaes, Lucas P. Carvalho, Tainã Lago, Augusto M. Carvalho, Rúbia Costa, and Edgar M. Carvalho
Author affiliations: Federal University of Bahia, Salvador, Brazil (P.R.L. Machado, A. Lago, A. Magalhaes, L.P. Carvalho, T. Lago, R. Costa, E.M. Carvalho); National Institute of Science and Technology of Tropical Diseases (INCT-DT), Brasília, Brazil (P.R.L. Machado, L.P. Carvalho, A.M. Carvalho, E.M. Carvalho); Fiocruz, Salvador (T.M. Cardoso, A. Magalhaes, L.P. Carvalho, A.M. Carvalho, R. Costa, E.M. Carvalho)

Main Article

Table 1

Demographic, clinical, laboratory, and therapeutic characteristics of DL and CL patients in study of leishmaniasis immune response and clinical and therapeutic outcomes, Corte de Pedra Health Post, Brazil, 2016–2019*

Characteristic DL, n = 101 CL, n = 101 p value
Age, y
 39.5 + 14.8
 32 + 13.3
 0.0002†
Sex, no. (%) patients.
M 88 (87) 69 (68) 0.04‡
F
 13 (13)
 23 (32)
 0.04‡
Duration of disease until diagnosis, d
 52.7 + 2.7
 41 + 1.7
 0.0003†
No. lesions 113.6 + 210 1.4 + 0.7 <0.0001†
Biggest lesion size, mm2
 775.6 + 2,190
 392.7 + 283.4
 NS
Lymphadenopathy, no. positive/no. tested (%) 47/93 (50.5) 61/101 (60.4) NS
LST size, mm2 102.3 + 96.5 213.6 + 126.9 0.0001†
LST , no. positive/no. tested (%) 64/97 (66) 101/101 (100) 0.0001‡
PCR. no. positive/no. tested (%) 84/91 (92) 101/101 (100) NS
Cure rate, no. cured/no. treated (%)§ 34/78 (44)¶ 44/101 (60) NS
Healing time, d§ 177 + 19.6 110.8 + 7.7 0.001†

*Values are mean + SD unless otherwise indicated. CL, cutaneous leishmaniasis; DL, disseminated leishmaniasis; LST, Leishmania skin test, NS, not significant. †By unpaired t-test. ‡By Fisher exact test. §After 1 standard course of meglumine antimoniate (20 mg/kg/d) for 20 d (CL) or 30 d (DL). ¶Six patients had no outcome data, irregular use, or discontinuation.

Main Article

Page created: January 26, 2024
Page updated: February 23, 2024
Page reviewed: February 23, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external